tesetaxel: Clinical Trials

12 trials of tesetaxel, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 unknown, 2 completed, 2 terminated. 12 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Unknown 8, Completed 2, Terminated 2
Phase 11Unknown 1

Follow tesetaxel: new trials by email Literature Review of tesetaxel trials Research Report on tesetaxel

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
Tesetaxel, Nivolumab, Pembrolizumab - Breast Cancer
Phase 2TerminatedOdonate Therapeutics, Inc.2942019-07-092021-07-30
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
Tesetaxel, Capecitabine - Breast Cancer
Phase 2TerminatedOdonate Therapeutics, Inc.1522019-02-052021-07-30
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Tesetaxel, Capecitabine - Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer
Phase 2UnknownGenta Incorporated2132012-05-012012-06-01
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Tesetaxel, Placebo, Capecitabine - Gastric Carcinoma
Phase 2UnknownGenta Incorporated5802012-04-012012-07-24
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Tesetaxel-capecitabine-cisplatin - Gastric Carcinoma
Phase 1 / Phase 2UnknownGenta Incorporated632011-05-012012-03-13
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Tesetaxel - Prostate Cancer
Phase 2UnknownGenta Incorporated572011-02-012012-07-24
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Tesetaxel once every 3 weeks, Tesetaxel once weekly - Breast Neoplasm
Phase 2UnknownGenta Incorporated812010-11-012012-07-24
Tesetaxel for Previously Treated Patients With Bladder Cancer
Tesetaxel - Carcinoma, Transitional Cell
Phase 2UnknownGenta Incorporated332010-09-012012-07-11
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Tesetaxel - Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Phase 2UnknownGenta Incorporated272010-03-012012-03-15
Phase II Study of Tesetaxel in Metastatic Melanoma
Tesetaxel - Advanced Melanoma, Cancer
Phase 2CompletedM.D. Anderson Cancer Center172010-02-012018-07-17
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Tesetaxel - Melanoma
Phase 2UnknownGenta Incorporated272010-02-012011-11-08
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
DJ-927 - Colorectal Cancer
Phase 2CompletedDaiichi Sankyo2004-02-012012-05-16

Conditions studied

Breast Neoplasms (4)  ·  Melanoma (2)  ·  Neoplasm Metastasis (2)  ·  Stomach Neoplasms (2)  ·  Carcinoma, Transitional Cell (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Rectal Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

Genta Incorporated (8)  ·  Odonate Therapeutics, Inc. (2)  ·  Daiichi Sankyo (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (11)  ·  South Korea (4)  ·  Taiwan (2)  ·  Australia (1)  ·  Canada (1)  ·  Germany (1)  ·  Italy (1)  ·  Singapore (1)  ·  Spain (1)

Top investigators

Andrew D Seidman, MD (2)  ·  Jaffer Ajani, MD (2)  ·  Agop Y Bedikian, MD (1)  ·  Agop Y. Bedikian, MD, BS (1)  ·  Dean F Bajorin, MD (1)  ·  Joseph O'Connell, M.D. (1)  ·  Joseph O'Connell, MD (1)  ·  Michael J Morris, MD (1)  ·  Peter Cheverton, MD, ChB, MMED, RadT (1)  ·  Sun Young Rha, MD, PhD (1)